1. ALLA AKTIER
  2. NYHETER
  3. NANEXA

Nanexa

Nyheter Nanexa Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Analysis of the first samples from the 30 mg dose group in the NEX-22 Phase I study shows continued promising results

Nanexa announced today that the first pharmacokinetic (PK) samples from the final dose group, 30 mg, in the ongoing Phase I study for NEX-22 have been analyzed. The results show that the PK profile is similar to that of previous dose groups and that plasma exposure continues to increase with higher doses.

“The NEX-22 study is an important part of our research and development, and these preliminary results are very encouraging”, says David Westberg, CEO Nanexa. “The results indicate that the treatment has a predictable and dose-dependent pharmacokinetic profile, which provides a good foundation for the upcoming Phase Ib study in the NEX-22 project. It is also a positive sign for the development of other long-acting injectable drugs with our PharmaShell technology.”

We look forward to completing this study after the final clinical visits taking place this week and to sharing further results as they become available.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ) 
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com

The company’s Certified Adviser is Carnegie Investment Bank AB (publ).

About Nanexa AB (publ)

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.

Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

Analysis of the first samples from the 30 mg dose group in the NEX-22 Phase I study shows continued promising results

Datum 2025-05-05, kl 11:55
Källa MFN
Bifogade filer
Analysis of the first samples from the 30 mg dose group in the NEX-22 Phase I study shows continued promising results